CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 46 enrolled
Drug / intervention
Abemaciclib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05440786
NCT05440786Phase 2Active
CompareCT.gov

A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma

Eli Lilly and Company·interventional·Posted Jul 1, 2022·Updated Apr 13, 2026

In Brief

A Phase 2 clinical trial evaluating Abemaciclib, Irinotecan, and 1 other intervention for Sarcoma, Ewing and Neoplasm Metastasis. Active but no longer recruiting, targeting 46 participants across 29 sites in 7 countries.

Detailed Summary

The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Ewing, Neoplasm Metastasis
CountriesAustralia, France, Germany, Italy, Japan, Spain, United States
Collaborators--

Timeline

Phase 2Active
20232024202520262027
First PostedJul 1, 2022
Enrollment StartSep 20, 2022
Primary CompletionJan 15, 2025
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.0 years ago

Interventions

Abemaciclibdrug

Orally

Irinotecandrug

IV

Temozolomidedrug

Orally